EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Scaling Autologous Epidermal Cell Therapies: iPSC ‐Derived Keratinocytes and In Vivo Chimerism for Skin Regeneration

Sina Kardeh, Mohsen Mazloomrezaei, Ahmad Hosseini

Experimental Dermatology · 2025

DOI: 10.1111/exd.70107 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Experimental Dermatology, 2025. Verfasst von Sina Kardeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Keratinocytes, Induced Pluripotent Stem Cells, Chimerism, Regeneration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe skin injuries and genetic disorders such as epidermolysis bullosa present significant clinical challenges due to limitations in current epidermal replacement therapies. While promising, cultured epithelial autografts (CEAs) suffer from prolonged culture times, cellular senescence, and low‐quality clinical outcomes, limiting their widespread application. Recent advancements in iPSC‐derived keratinocytes (iKeratinocytes) and in vivo chimerism offer transformative potential for scalable and personalised skin regeneration. Advances in understanding transcriptional networks, mRNA delivery, CRISPR‐based genome editing, and automated biomanufacturing processes can enable improved and efficient protocols for generating iKeratinocytes. Despite these advances, there are still challenges for scaling iKeratinocytes, including optimising xeno‐free culture systems and developing reproducible methods for generating multilayered skin with appendages. Interspecies chimerism utilising lineage‐specific ablation systems and targeted in utero delivery of organ progenitor cells can enable human epidermal tissue development within animal hosts, offering an alternative novel platform for scaling epidermal cell and skin generation. This method, however, requires further refinements for complete ablation and detachment of target cells in the animal hosts and improved human cell integration in chimeric models. Together, iKeratinocytes and in vivo chimerism hold great promise for advancing autologous epidermal cell therapies and enabling broader clinical adoption and improved outcomes for patients with severe skin injuries and genetic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KeratinocytesInduced Pluripotent Stem CellsChimerismRegenerationCell- and Tissue-Based TherapyHumansAnimalsTransplantation, AutologousEpidermis

Stichwörter der Autor:innen

iPSCepidermiskeratinocytesregenerative medicineskin

Autor:innen und Institutionen

  • Center for Engineering in Medicine and Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • Shriners Hospital for Children, Boston, Massachusetts, USA.
  • Vascularized Composite Allotransplantation Laboratory, Massachusetts General Hospital, Boston, Massachusetts, USA.

Zitieren

APA

Kardeh, S., Mazloomrezaei, M., & Hosseini, A. (2025). Scaling Autologous Epidermal Cell Therapies: iPSC ‐Derived Keratinocytes and In Vivo Chimerism for Skin Regeneration. Experimental Dermatology. https://doi.org/10.1111/exd.70107

Vancouver

Kardeh S, Mazloomrezaei M, Hosseini A. Scaling Autologous Epidermal Cell Therapies: iPSC ‐Derived Keratinocytes and In Vivo Chimerism for Skin Regeneration. Experimental Dermatology. 2025. doi:10.1111/exd.70107

BibTeX
@article{Kardeh2025,
  author = {Kardeh, Sina and Mazloomrezaei, Mohsen and Hosseini, Ahmad},
  title = {Scaling Autologous Epidermal Cell Therapies: iPSC ‐Derived Keratinocytes and In Vivo Chimerism for Skin Regeneration},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70107}
}
Kostenlos starten →